A Game Changer in Novel Drug Development
A Game Changer in Novel Drug Development
A Game Changer in Novel Drug Development
> ABOUT US > Overview
Korea’s Leading Antibody Therapeutics Development Company
Y-Biologics develops novel antibody-based therapeutics through proprietary pipeline and strategic partnerships, leveraging our globally competitive antibody discovery technologies.
By continuously developing innovative new drugs, we aim to be a global leader in antibody therapeutics.
Korea’s Leading Antibody Therapeutics Development Company
Korea’s Leading Antibody Therapeutics Development Company
Korea’s Leading Antibody Therapeutics Development Company
Y-Biologics develops novel antibody-based therapeutics through proprietary pipeline and strategic partnerships, leveraging our globally competitive antibody discovery technologies.
By continuously developing innovative new drugs, we aim to be a global leader in antibody therapeutics.
Y-Biologics develops novel antibody-based therapeutics through proprietary pipeline and strategic partnerships, leveraging our globally competitive antibody discovery technologies.
By continuously developing innovative new drugs, we aim to be a global leader in antibody therapeutics.
Y-Biologics develops novel antibody-based therapeutics through proprietary pipeline and strategic partnerships, leveraging our globally competitive antibody discovery technologies.
By continuously developing innovative new drugs, we aim to be a global leader in antibody therapeutics.
“
Developing the next generation of cancer therapies based on leading antibody technologies
Multi-AbKine :
Next Generation Immuno-oncology
Innovative Immuno-Oncology Therapeutic, Multi-AbKine
Innovative Immuno-Oncology Therapeutic, Multi-AbKine
Y-Biologics is addressing unmet medical needs by developing next-generation Multispecific Antibody-Cytokine Fusion molecules (Multi-AbKine) designed to overcome cancers that are unresponsive or resistant to existing immunotherapies.
• Multi-AbKine, a next-generation immuno-oncology agent in Y-Biologics’ proprietary pipeline, is a multi-functional fusion protein combining bispecific antibodies with cytokines. It is designed to overcome cancers resistant to conventional immunotherapies.
• With the development of Multi-AbKine, Y-Biologics is expanding its capabilities in the cytokine field and will continue to actively address unmet medical needs through novel and innovative approaches to cancer treatment.
• Multi-AbKine, a next-generation immuno-oncology agent in Y-Biologics’ proprietary pipeline, is a multi-functional fusion protein combining bispecific antibodies with cytokines. It is designed to overcome cancers resistant to conventional immunotherapies.
• With the development of Multi-AbKine, Y-Biologics is expanding its capabilities in the cytokine field and will continue to actively address unmet medical needs through novel and innovative approaches to cancer treatment.
• Y-Biologics has achieved technology transfers and joint development agreements with global partners based on its world-class fully human antibody library and antibody engineering technology.
• Leveraging its advanced antibody platform, Y-Biologics can develop not only bispecific antibodies but also diverse modalities such as antibody humanization (VHH nanobody), pH-dependent antibodies, and ADCs, enabling the discovery of antibodies for various applications.
• Y-Biologics has achieved technology transfers and joint development agreements with global partners based on its world-class fully human antibody library and antibody engineering technology.
• Leveraging its advanced antibody platform, Y-Biologics can develop not only bispecific antibodies but also diverse modalities such as antibody humanization (VHH nanobody), pH-dependent antibodies, and ADCs, enabling the discovery of antibodies for various applications.
• Y-Biologics has achieved technology transfers and joint development agreements with global partners based on its world-class fully human antibody library and antibody engineering technology.
• Leveraging its advanced antibody platform, Y-Biologics can develop not only bispecific antibodies but also diverse modalities such as antibody humanization (VHH nanobody), pH-dependent antibodies, and ADCs, enabling the discovery of antibodies for various applications.
• Y-Biologics has achieved technology transfers and joint development agreements with global partners based on its world-class fully human antibody library and antibody engineering technology.
• Leveraging its advanced antibody platform, Y-Biologics can develop not only bispecific antibodies but also diverse modalities such as antibody humanization (VHH nanobody), pH-dependent antibodies, and ADCs, enabling the discovery of antibodies for various applications.
• Y-Biologics has achieved technology transfers and joint development agreements with global partners based on its world-class fully human antibody library and antibody engineering technology.
• Leveraging its advanced antibody platform, Y-Biologics can develop not only bispecific antibodies but also diverse modalities such as antibody humanization (VHH nanobody), pH-dependent antibodies, and ADCs, enabling the discovery of antibodies for various applications.
Innovative Immuno-Oncology Therapeutic, Multi-AbKine
• Multi-AbKine, a next-generation immuno-oncology agent in Y-Biologics’ proprietary pipeline, is a multi-functional fusion protein combining bispecific antibodies with cytokines. It is designed to overcome cancers resistant to conventional immunotherapies.
• With the development of Multi-AbKine, Y-Biologics is expanding its capabilities in the cytokine field and will continue to actively address unmet medical needs through novel and innovative approaches to cancer treatment.